Related by context. All words. (Click for frequent words.) 67 multicentre prospective 67 retrospective cohort 66 prospective multicentre 66 BEXXAR Therapeutic Regimen 65 longitudinal cohort study 64 EURIDIS 64 limiting generalizability 64 atherothrombotic disease 64 nonrandomized 64 Randomized controlled 64 Swedish Mammography Cohort 63 relapsed MM 63 clinically evaluable 63 prelicensure 63 HIV HCV coinfected 63 Primary endpoints 63 prospective observational cohort 63 prospective multicenter study 62 venous thromboembolic disease 62 IMPROVE HF 62 observational cohort study 62 prospective cohort 62 liver transplant recipients 62 double blinded randomized 62 trials RCTs 62 STRIDE PD 62 prospective longitudinal 62 PLCO 62 prospectively defined 61 COPERNICUS 61 Wisconsin Sleep Cohort 61 atherosclerotic renal artery stenosis 61 Health Initiative Observational 61 VADT 61 CHAMPION PCI 61 EchoCRT 61 carotid artery stenting CAS 61 ABSSSI 61 randomized controlled trials RCTs 61 GH deficiency 61 prospective observational 61 colorectal adenoma 61 placebo controlled Phase III 61 urolithiasis 61 NCT# ClinicalTrials.gov 61 pain palliation 61 nutrient supplementation 61 Combination antiretroviral therapy 61 Multicenter AIDS 61 ALI ARDS 61 ExTRACT TIMI 61 multicentre randomized 61 perinatal outcomes 61 retrospective cohort study 61 prospective observational studies 60 randomizing patients 60 prospectively randomized 60 Atherosclerosis MESA 60 Carotid Revascularization Endarterectomy vs. 60 microbiologically evaluable 60 patients undergoing percutaneous 60 urothelial cancer 60 nonpregnant women 60 Prostate Lung Colorectal 60 T1DM 60 Haptoglobin 60 prospective randomized multicenter 60 efficacy evaluable 60 atherogenic dyslipidemia 60 Digital Mammographic Imaging 60 multicenter randomized controlled 60 blinded randomized controlled 60 HIV uninfected 60 riociguat 60 quinacrine 60 RE LY ® 60 aldosterone antagonist 60 KRAS mutations occur 60 atherothrombotic 60 recurrent venous thromboembolism 60 antiretroviral naïve 60 PRoFESS 60 androgen suppression 60 HIV seronegative 60 ASPIRE HIGHER 60 perinatal morbidity 60 AIM HIGH 60 thromboprophylaxis 60 multiple logistic regression 60 retrospective observational study 60 Trandolapril 59 HER2 overexpression 59 Multi Ethnic Study 59 UKPDS 59 placebo controlled clinical 59 randomized multicenter trial 59 tolerability pharmacokinetics 59 SORT OUT III 59 controlled multicenter 59 Val HeFT 59 oral prednisolone 59 multivariable Cox 59 logistic regression models 59 ELBW infants 59 BPS IC 59 IPAH 59 meta regression 59 colorectal cancer incidence 59 NICE SUGAR 59 protease inhibitor PI 59 oral FTY# 59 pretransplant 59 advanced adenoma 59 Prospective Randomized 59 multivariate Cox 59 Multiethnic Cohort Study 59 DAS# scores 59 DAPT Study 59 PCWP 59 orofacial clefts 59 VTE prophylaxis 59 CHD mortality 59 histologic subtype 59 LUX Lung 59 pulmonary embolism PE 59 NSABP B 59 randomized blinded 59 ADMIRE HF 59 HYVET 59 myocardial infarctions MIs 59 HF ACTION 59 Liraglutide Effect 59 pharmacodynamic PD 59 MERLIN TIMI 59 BR.# 59 dyslipidaemia 59 TAXUS VI 59 CaPSURE 59 Zemplar Capsules 59 undergoing coronary angiography 59 β blockers 59 histologically confirmed 59 Edge STudy 59 coronary revascularization 59 PLX STROKE targeting 59 histological subtype 59 BCIRG 59 bronchopulmonary dysplasia BPD 59 Meta analyzes 59 beta carotene supplementation 59 treatment naive genotype 59 ONTARGET 59 NNT = 59 poor metabolizers 59 abacavir Ziagen 59 prospectively stratified 59 INTERHEART 59 multicentre 59 substudy 59 ragweed allergic 59 CTEPH 59 clinico pathological 59 ascending dose 59 INTERHEART study 59 Intervention Trial 59 undergone radical prostatectomy 59 CHD CVD 59 preintervention 59 CARDIA study 59 Dialysis Outcomes 58 HORIZONS AMI trial 58 metastatic neuroendocrine tumors 58 Alpha Tocopherol Beta Carotene 58 etiologic 58 multicenter trials 58 mutated K ras 58 prostate cancer PCa 58 Baseline characteristics 58 femoral neck fracture 58 multicenter randomized placebo controlled 58 thyrotropin levels 58 postoperative AF 58 dysglycemia 58 HER2 expression 58 lignan intake 58 nulliparous women 58 prostate cancer CaP 58 quadrivalent HPV vaccine 58 Chronic Heart Failure 58 MADIT II 58 NIHSS score 58 WHEL 58 NHANES III 58 Subgroup analyzes 58 iPrEx study 58 REYATAZ ritonavir 58 HCV SPRINT 58 Subarachnoid hemorrhage 58 IDDM 58 definite stent thrombosis 58 MAGE A3 ASCI 58 chronic periodontitis 58 nondiabetic patients 58 differential gene expression 58 REALITY Trial 58 TAXUS ARRIVE 58 thromboembolic complications 58 relapsed ALL 58 spontaneous preterm delivery 58 familial clustering 58 onset diabetes mellitus 58 blinded randomized placebo controlled 58 TMC# C# 58 bepotastine besilate nasal spray 58 genotypic resistance 58 RRMS patients 58 tumor histology 58 SCD HeFT 58 recurrent glioblastoma multiforme 58 LHON 58 GOUT 58 velafermin 58 Prostate Cancer Prevention 58 multicenter randomized 58 multicentre study 58 clinicopathologic 58 morphometric vertebral fractures 58 NATRECOR R 58 de novo AML 58 CARE HF 58 dose escalation phase 58 P. falciparum malaria 58 Ovarian Cancer Screening 58 Pneumococcal vaccination 58 subgroup analyzes 58 GRNCM1 58 prospective multicenter 58 multicenter Phase II 58 symptomatic VTE 58 CYP#D# inhibitor 58 Scandinavian Simvastatin Survival 58 GAMMAGARD 58 carotid artery stenting 58 lipid lowering drugs 58 hematopoietic cancers 58 Rheos System 58 subclinical atherosclerosis 58 relapsing remitting MS RRMS 58 antioxidant supplementation 58 lipid lowering agents 58 LUMINATE 58 Phase III multicenter 58 overt nephropathy 58 Randomized Evaluation 58 Cohort Consortium 58 sociodemographic factors 58 multivariable adjusted 58 ACTEMRA TM 58 randomized multicenter 58 Severe Primary IGFD 58 NIDDM 58 Erythropoietic therapies may 58 intensive lipid lowering 58 recurrent VTE 58 invasive aspergillosis 58 guideline concordant 58 HSCT 58 Proellex TM 58 Secondary efficacy endpoints 58 TEAEs 58 NO# [002] 58 atherothrombosis 58 parous 58 macrovascular disease 58 antibiotic regimens 58 AIR2 Trial 58 inhaled budesonide 58 carotid plaques 58 proliferative retinopathy 57 advanced neoplasia 57 GnRH agonist 57 Bayer HealthCare Onyx Pharmaceuticals 57 DVT PE 57 WHIMS 57 direct thrombin inhibitors 57 placebo controlled randomized 57 serum lipid levels 57 kidney transplant recipients 57 antithrombotic therapy 57 SEER database 57 Ceplene/IL-2 57 blinded placebo controlled 57 postoperative atrial fibrillation 57 Thrombolysis 57 Framingham Offspring Study 57 Atherosclerosis Risk 57 suboptimal adherence 57 generalisable 57 odds ratios ORs 57 comorbid psychiatric disorders 57 Platinol ® cisplatin 57 Multivariate logistic regression 57 Women Ischemia Syndrome 57 recurrent miscarriage 57 Left Ventricular Dysfunction 57 prostate carcinogenesis 57 BENICAR HCT 57 pimecrolimus cream 57 CYT# potent vascular disrupting 57 cluster randomized controlled 57 cerebral vasospasm 57 allogeneic HSCT 57 ARB telmisartan 57 CIMZIA TM certolizumab pegol 57 locoregional 57 Multicenter Automatic Defibrillator Implantation 57 immunochemical fecal occult 57 Xelox 57 multicenter randomized clinical 57 VLBW 57 BARI 2D 57 Heavy menstrual bleeding 57 CVD mortality 57 subclinical hypothyroidism 57 Phase 2b dose 57 ConclusionThis 57 Diabetes Interventions 57 multicenter prospective 57 psychiatric comorbidities 57 logistic regression model 57 GYTS 57 Common Toxicity Criteria 57 MGd 57 B streptococcal 57 GVAX Pancreas Vaccine 57 aged ≥ 57 Renal dysfunction 57 fetal chromosomal 57 thromboembolic disease 57 NYHA functional class 57 multivessel disease 57 HGPIN 57 patients undergoing CABG 57 Cardiac Allograft Rejection 57 Stenting Trial CREST 57 confirmatory clinical 57 Screening Trial DMIST 57 Cardiotoxicity 57 probiotic supplementation 57 hepatitis C genotype 57 FluCAM arm 57 clinicopathological 57 ENGAGE AF TIMI 57 CARDIA 57 certolizumab 57 clinically localized prostate 57 invasive candidiasis 57 Cloretazine 57 MDRD 57 thorough QT 57 Phase #/#a 57 RE SURGE 57 congenital toxoplasmosis 57 thrombocytopenic 57 MADIT 57 double blinded placebo 57 nucleoside naive patients 57 Kaplan Meier curve 57 ß blockers 57 controlled dose escalation 57 pegylated interferon alfa 2b 57 prasterone 57 hyperphenylalaninemia HPA due 57 kidney urologic 57 ACCORD Lipid 57 cobiprostone 57 Prostate AdenoCarcinoma Treatment 57 nonvertebral fractures 57 HbA1C levels 57 REGARDS 57 attain statistical significance 57 CATIE AD 57 pharmacologic intervention 57 internalizing disorders 57 coinfected patients 57 nonmetastatic 57 null responder 57 IntroductionThe 57 postintervention 57 canakinumab 57 KIF6 carriers 57 sociodemographic characteristics 57 prospective nonrandomized 57 Decompensated Heart Failure 57 symptomatic BPH 57 Ovarian PLCO Cancer 57 recurrent glioma 57 PhG alpha 1 57 aspartate aminotransferase AST 57 Reynolds Risk Score 57 papillary renal cell carcinoma 57 multicenter multinational 57 incomplete revascularization 57 Acute Decompensated Heart Failure 57 visceral metastases 57 treatment naïve genotype 57 DHEA supplementation 57 hepatorenal syndrome 57 metaanalysis 57 pharmacokinetic pharmacodynamic 57 placebo controlled studies 57 underwent resection 57 aspirin clopidogrel 57 cardio renal 57 inhaled tobramycin 57 EuroSCORE 57 Osteoporotic Fractures 57 Zevalin consolidation 57 ENDEAVOR clinical 57 multicentric 57 chorioamnionitis 57 REVIVE Diabetes 57 RSD# oral 57 stratifying patients 57 Young Adults CARDIA 57 μg L 57 intravenous RSD# 57 AML MDS 57 chemoprevention trials 57 cytoreductive nephrectomy 56 genetic variants associated 56 Replication NCS R 56 LV dysfunction 56 CALGB 56 lanthanum carbonate 56 dacarbazine chemotherapy 56 RESOLUTE clinical 56 aldosterone antagonists 56 mean ± SEM 56 Postoperative complications 56 lupus renal disease 56 Memory Study WHIMS 56 strontium ranelate 56 GORE VIABAHN Endoprosthesis 56 plasma pharmacokinetics 56 carotid revascularization 56 prospective randomized controlled 56 nonsevere 56 RELOVAIR ™ 56 CC genotype 56 NATRECOR ® 56 CANCIDAS 56 postmenopausal hormone 56 oncologic outcomes 56 malaria endemic regions 56 OLYMPIA registry 56 ritonavir boosted lopinavir 56 undergo percutaneous coronary 56 paclitaxel eluting stents 56 inhaled bronchodilators 56 immunosuppressive regimens 56 Intervention Trial GAIT 56 pharmacodynamic parameters 56 phase Ib 56 inhospital 56 BRCA mutation carriers 56 hip resurfacing arthroplasty 56 COU AA 56 Insulin Resistance Atherosclerosis 56 fulminant hepatic failure 56 baseline LDH 56 Percutaneous Coronary Interventions 56 placebo controlled trials 56 RCTs 56 primary hyperparathyroidism 56 azilsartan medoxomil 56 KRAS status 56 hormone receptor status 56 ICD therapy 56 metastatic HRPC 56 residual confounding 56 metachronous 56 PNH patients 56 Multiethnic Study 56 LAB CGRP 56 logistic regression analysis 56 anthropometric measures 56 randomized discontinuation 56 circulating endothelial cells 56 Hepatocellular Carcinoma HCC 56 newer atypical antipsychotics 56 NOMID 56 nonvertebral fracture 56 PROactive study 56 angiographically 56 Exelixis XL# 56 venous thromboembolic events 56 Uncontrolled hypertension 56 mITT 56 valent pneumococcal conjugate vaccine 56 ARIXTRA 56 Tasigna prolongs 56 PFO migraine 56 phase IIIb 56 heavily pretreated 56 LibiGel Phase III 56 perioperative morbidity 56 Phase IIIb clinical 56 HBeAg negative 56 CAPRIE 56 HIV coinfected 56 oncological outcomes 56 linear regression analyzes 56 postoperative chemotherapy 56 prognostic variables 56 prevalences 56 PHPT 56 Study AREDS 56 malignant neoplasm 56 Rilonacept 56 SYNTAX 56 neurocognitive outcomes 56 mg BID dose 56 Group RTOG 56 cytomegalovirus infection 56 NNRTI resistance 56 antiarrhythmic drug 56 Afatinib 56 carotid stenosis 56 OSAHS 56 GnRH agonists 56 SIMPADICO 56 IMPACT DCM 56 clevidipine 56 System IPSS 56 Study ARIC 56 pharmacokinetic PK 56 subanalysis 56 multivitamin supplementation 56 fragility fractures 56 National Emphysema Treatment 56 inflammatory biomarkers 56 HIV seropositive 56 deCODE AF TM 56 chronic HCV infection 56 ICD implantation 56 generalizability 56 Non inferiority 56 symptomatic carotid stenosis 56 bladder augmentation 56 NSTE ACS 56 Screening Trial 56 microscopic colitis 56 cilostazol 56 blinded randomized 56 abnormal cytology 56 randomized controlled clinical 56 CYPHER Stent 56 hemodialysis patients 56 designated HVTN 56 randomized multicentre 56 longitudinal observational study 56 randomized controlled trials 56 MIST II 56 genomic biomarker 56 epidemiologic studies 56 Multicenter 56 ovulatory cycles 56 VLBW infants 56 acute coronary syndromes ACS 56 SYNTAX trial 56 Subgroup analysis 56 dengue haemorrhagic fever DHF 56 echocardiographic parameters 56 TransVax ™ 56 nonfatal MI 56 trivalent inactivated influenza 56 cat dander allergy 56 poststroke depression 56 Plasmodium falciparum malaria 56 renal scarring 56 Kaplan Meier analysis 56 germline mutations 56 bile acid metabolism 56 Poisson regression 56 neurosensory 56 glucocorticoid induced osteoporosis 56 HBV vaccination 56 Juvenile Idiopathic Arthritis 56 pulmonary hypertension PH 56 KRAS mutation 56 unstable angina pectoris 56 renal tumors 56 dosage regimens 56 Intervention Effectiveness 56 LHRH receptor positive 56 cerebral microbleeds 56 gonococcal 56 NLSY 56 serum leptin 56 multivessel coronary artery 56 coronary revascularisation 56 neoadjuvant 56 Nesiritide 56 Angiox R 56 distal colon cancer 56 reduce serum phosphate 56 SE5 OH containing 56 PRIMO CABG 56 Premature menopause 56 adenoma recurrence 56 sternal wound infections 56 subtrochanteric 56 testosterone supplementation 56 placebo controlled dose escalation 56 histologically proven 56 Fabry Disease 56 lipid lowering therapy 56 nonmelanoma skin cancers 56 Chronic HCV 56 EQUIP OB 56 GIK infusion 56 candesartan 56 EMPHASIS HF 56 LTBI 56 retrospective observational 56 Fibrillex TM 56 hyperhomocysteinemia 56 Renal Cell Carcinoma RCC 56 Clinical Antipsychotic Trials 56 cardioembolic stroke 56 perioperative mortality 56 nucleotide analog 56 endometrial hyperplasia 56 endometriosis ovarian cysts 56 underwent CABG 56 antiepileptics 56 chlamydial infections 56 APTIVUS r 56 undergone hysterectomies 56 STEP BD 55 composite endpoint 55 metastatic GIST 55 biologic DMARD 55 ovarian carcinoma 55 Ranolazine 55 comorbid illnesses 55 ACCORD Eye 55 atopic disorders 55 NSQIP 55 FDG PET scans 55 fusion enhancers 55 postexposure prophylaxis 55 Radical prostatectomy 55 % CI #.#-#.# [003] 55 anthropometric measurements 55 HER2 positive cancers 55 NP2 Enkephalin 55 thiopurine 55 salmeterol fluticasone propionate 55 Cytogenetic 55 masked placebo controlled 55 Logistic regression 55 Pneumococcal vaccines 55 decompensated liver disease 55 APEX AMI trial 55 CYP#D# genotype 55 randomized controlled 55 multivariate logistic regression 55 pathologic fractures 55 non valvular atrial 55 Patient Registry 55 elevated triglyceride levels 55 Kaplan Meier curves 55 attending antenatal clinics 55 pharmacokinetic interaction 55 atherosclerosis regression 55 nonfasting triglyceride levels 55 metaplasia 55 ToGA 55 APPRAISE 55 latent celiac disease 55 ACOSOG Z# 55 antiplatelet therapies 55 nonpharmacologic 55 randomized controlled multicenter 55 carotid atherosclerosis 55 Dietary Modification Trial 55 laboratory abnormalities 55 facial clefts 55 Coronary Artery Bypass Graft 55 heritable diseases 55 number NCT# ClinicalTrials.gov 55 Adjuvant chemotherapy 55 recurrent metastatic 55 PRECISE 55 antiangiogenic therapy 55 multivariable analysis 55 neratinib 55 Multiple logistic regression 55 invasive carcinoma 55 BLLs 55 Complications Trial 55 underwent percutaneous coronary 55 null responder HCV 55 plasma selenium 55 conjugated equine estrogen 55 ABCB1 55 psychiatric outpatients 55 preoperative chemotherapy 55 SSc 55 antiretroviral naive 55 electrophysiologic 55 ASCUS 55 metastatic malignant 55 vidofludimus 55 basal cell nevus syndrome 55 revascularization procedures 55 SCIg 55 oral anticoagulation 55 Adaptive Radiation Therapy 55 serum IGF 55 convergent validity 55 ARIXTRA R 55 periprocedural 55 multivariable analyzes 55 FOSRENOL ® 55 pretest probability 55 Estrogen Receptor 55 lipid lowering medication 55 resected pancreatic cancer 55 Vascugel ® 55 follicular lymphoma FL 55 ICAEL 55 Acute myocardial infarction 55 multiple linear regression 55 developmental neurotoxicity 55 Truvada tablets 55 conducted retrospective cohort 55 carotid bruit 55 serum homocysteine 55 SWOG 55 HCV RESPOND 2 55 PRE SURGE 55 VTEs 55 ID NCT# 55 Vasogen Celacade 55 multicenter Phase III 55 spontaneous regression 55 arterial thromboembolic events 55 multicenter study 55 transrectal ultrasound guided 55 antithrombotic agents 55 Phase III ThermoDox 55 juvenile idiopathic arthritis JIA 55 dosing cohort 55 antiplatelet medications 55 Current Controlled Trials 55 undergoing peritoneal dialysis 55 ARCOXIA 55 coronary revascularization procedures 55 ECASS 55 interstitial brachytherapy 55 intravenous diuretics 55 Western Airborne Contaminants 55 BioMarck 55 renal cortical 55 dose escalation Phase 55 folate supplementation 55 glycosylated hemoglobin levels 55 HeFH 55 bazedoxifene conjugated estrogens 55 Exacerbations 55 intracranial hemorrhage ICH 55 RoACTEMRA 55 LNG IUS 55 PK PD modeling 55 evaluable subjects 55 obstructive coronary artery 55 newer antipsychotic medications 55 HPTN 55 intra abdominal abscess 55 nonoperative 55 EGFR HER2 55 polytherapy 55 ROTARIX 55 noncardiac 55 osteoporotic compression fractures 55 tapentadol ER 55 By JENNIFER LEARN 55 Aspergillus infections 55 dyslipidemia hypertension diabetes 55 prospective multicenter randomized 55 venous blood clots 55 biliary tract cancer 55 risk reducing salpingo 55 thetreatment 55 haematologic 55 arterial thromboembolic 55 macrovascular events 55 superficial bladder cancer 55 CINQUIL 55 novel VDA molecule 55 forodesine 55 CPAP adherence 55 cytologic 55 sunitinib malate 55 adenomatous 55 rosuvastatin #mg 55 toenail onychomycosis 55 Phase III randomized 55 comorbid disorders 55 Cervical Cytology 55 pneumococcal carriage 55 Pivotal Trial 55 rosuvastatin Crestor 55 thrombophilia 55 CLBP 55 Thyroid nodules 55 glycated hemoglobin levels 55 FDA defined valvulopathy 55 coronary calcification 55 Human Hookworm Vaccine Initiative 55 immunocompetent 55 adverse cytogenetics 55 MDRD equation 55 serum retinol 55 RECORD1 55 lipid elevations 55 CORE OM 55 NYHA 55 KDOQI 55 demonstrated clinically meaningful 55 gonococcal infections 55 myocardial viability 55 meta analytic 55 SRBD 55 unstable angina UA 55 receiving antiretroviral therapy 55 gestational hypertension 55 MEND CABG 55 See CLINICAL PHARMACOLOGY 55 vWD 55 somatostatin analog 55 intact parathyroid hormone 55 capsular polysaccharide 55 bladder carcinoma 55 bivariate analyzes 55 transcatheter closure 55 transcervical 55 ACCOMPLISH 55 viral kinetics 55 gallstone disease 55 stable angina 55 biologic DMARDs 55 randomized trials 55 postdischarge 55 Adverse effects 55 singleton pregnancy 55 SWiTCH 55 gastric cardia 55 familial aggregation 55 ertapenem 55 bronchial hyperresponsiveness 55 Rectal cancer 55 colorectal carcinogenesis 55 underwent liver transplantation 55 eplerenone 55 Vascugel 55 symptomatic paroxysmal AF 55 nonsmall cell lung cancer 55 caspofungin 55 Ischemic 55 esophageal squamous cell carcinoma 55 NOD mouse 55 conditional logistic regression 55 multicenter randomized double 55 Diamyd r 55 parous women 55 antiviral prophylaxis 55 lacunar 55 randomized multicenter Phase III 55 randomized clinical 55 Teriflunomide 55 sleeve lobectomy 55 nondemented 55 galiximab 55 Phase Ib II 55 preimplantation genetic screening 55 ADHERE 55 flutamide 55 Randomized trials 55 coronary revascularizations 55 methodologically rigorous 55 pharmacological therapies 55 androgen deprivation 55 hepatectomy 55 antitumor effect 55 AST ALT 55 knee osteoarthritis OA 55 coinfection 55 SHPT 55 curative resection 55 external genital lesions 55 ELCAP 55 PAOD 55 mildly symptomatic 54 Retreatment 54 airway responsiveness 54 pretreatment serum 54 histopathologic diagnosis 54 registrational Phase 54 allergen avoidance 54 autonomic dysfunction 54 aromatase inhibitors AIs 54 vaccinees 54 protease inhibitor mutations 54 XIENCE V Stent System 54 prognostic indicators 54 Non Alcoholic Steatohepatitis 54 VaD 54 nonischemic 54 peritoneal cancer 54 Wactawski Wende 54 operable breast cancer 54 perfusion abnormalities 54 Coronary artery bypass graft 54 ABSORB trial 54 OnDose TM 54 venlafaxine XR 54 AREDS 54 unmeasured confounders 54 multicentre randomized controlled 54 bicuspid aortic valves 54 serum GGT 54 multivariate analyzes 54 onset AF 54 polysaccharide vaccines 54 REMINYL ® 54 thromboembolic 54 mesotheliomas 54 Arch Intern Med 54 octreotide LAR 54 chromium supplementation 54 APTIVUS 54 bilateral oophorectomy 54 T2DM 54 gadobutrol 54 nodal metastasis 54 thoracoscopic lobectomy 54 QTc prolongation 54 conjugate vaccines 54 oesophageal adenocarcinoma 54 HPV subtypes 54 Institute DCRI 54 seroprevalence 54 daily subcutaneous injections 54 serum selenium 54 transplantation HSCT 54 landmark ATHENA 54 impaired insulin secretion 54 CURRENT OASIS 7 54 phase IIa 54 Avandia Actos 54 lipid lowering therapies 54 BRIM3 54 targeting miR 54 monogenic 54 de aths 54 Sociodemographic 54 medically inoperable 54 RESIST studies 54 atypical Hemolytic Uremic Syndrome 54 metastatic RCC 54 topical NSAIDs 54 Netherlands Cohort Study 54 shorter telomere length 54 Topical corticosteroids 54 generalisability 54 acute myocardial infarctions 54 antithrombotics 54 Betaferon R 54 recurrent UTI 54 heterozygous familial 54 prospectively enrolled 54 PCI percutaneous coronary 54 non adjuvanted vaccines 54 APOE genotype 54 AI AN 54 logistic regression analyzes 54 functional mitral regurgitation 54 nonalcoholic steatohepatitis 54 Complication rates 54 albumin excretion 54 Cholesterol Levels SPARCL 54 patientswith 54 genomewide 54 carotid plaque 54 NSTEMI